Get the Stockscreener App
0.00
100.00%
-14.00
After Hours:
13.99
13.99
+
Ventyx Biosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$14.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-106.61M
P/E Ratio:
0.00
EPS:
-1.4995
Net Cash Flow:
$-87.87M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(760) 407-6511
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
0.00 | 1.00B | 0 | -106.61M | -87.87M | -1.4995 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Will Ventyx Biosciences Inc stock hit new highs in YEAR2026 Stock Rankings & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Aug Decliners: Is Ventyx Biosciences Inc forming a double bottomStop Loss & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Published on: 2026-03-27 07:56:14 - baoquankhu1.vn
Ventyx Biosciences stock faces uncertainty after pipeline setback and strategic review - AD HOC NEWS
If You Invested $1,000 in Ventyx Biosciences, Inc. (VTYX) - stocktitan.net
Market Fear: How does Ventyx Biosciences Inc score in quality rankings2026 Trading Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Aug PostEarnings: Can Ventyx Biosciences Inc benefit from deglobalizationEarnings Trend Report & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aug Swings: Is Ventyx Biosciences Inc stock forming a triangle pattern2026 Stock Rankings & Capital Efficient Trading Techniques - baoquankhu1.vn
[15-12G] Ventyx Biosciences, Inc. SEC Filing - Stock Titan
LifeSci Capital downgrades Ventyx Biosciences (VTYX) - MSN
Growth Recap: Does Ventyx Biosciences Inc stock reflect fundamentalsWeekly Trade Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Breakout Move: Is Ventyx Biosciences Inc stock overvalued or fairly priced2026 Update & Consistent Profit Trading Strategies - baoquankhu1.vn
[EFFECT] Ventyx Biosciences, Inc. SEC Filing - stocktitan.net
Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study - MSN
Ventyx Biosciences (NASDAQ:VTYX) Upgraded to Hold at Wall Street Zen - MarketBeat
Why Ventyx Biosciences Inc. stock is rated strong buyJuly 2025 Weekly Recap & High Return Trade Guides - Naître et grandir
Lilly nearing $1 billion deal with biotech Ventyx, WSJ says - MSN
Assessing Ventyx Biosciences (VTYX) Valuation After A Sharp 90 Day Share Price Rebound - simplywall.st
Eli Lilly buys Ventyx (VTYX) in all-cash $14 per share merger - Stock Titan
Ventyx Biosciences Completes Cash Merger and Equity Payout - theglobeandmail.com
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Ventyx Biosciences (VTYX) exec records option dispositions in $14 Lilly buyout - Stock Titan
Ventyx Biosciences (VTYX) cashed out at $14 per share in Eli Lilly merger - Stock Titan
COO’s Ventyx (VTYX) options cashed out as Eli Lilly merger closes - Stock Titan
Lilly–Ventyx (VTYX) merger cancels director stock options at $14 - Stock Titan
Ventyx Biosciences (VTYX) director’s options cancelled in Eli Lilly cash merger - Stock Titan
Ventyx (VTYX) director’s options and shares cashed out at $14 in Eli Lilly merger - Stock Titan
Eli Lilly deal converts Ventyx (VTYX) CMO’s shares and options to cash - Stock Titan
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Ventyx Biosciences (VTYX) deregisters registered resale shares after merger - Stock Titan
Ventyx Biosciences (NASDAQ: VTYX) deregisters shares after Eli Lilly merger - Stock Titan
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Ventyx Biosciences (VTYX) notifies Nasdaq of common stock delisting - Stock Titan
Ventyx Biosciences Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Ventyx Biosciences (NASDAQ: VTYX) shareholders get $14 cash in Eli Lilly buyout - Stock Titan
Ventyx (VTYX) CEO cashes out stock and options in $14 Eli Lilly merger - stocktitan.net
VTYX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc.(VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences Shareholders Approve Merger With Eli Lilly - TipRanks
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from NASDAQ Composite Index - marketscreener.com
Ventyx Biosciences shareholders approve merger with Eli Lilly By Investing.com - Investing.com South Africa
Ventyx Biosciences shareholders approve merger with Eli Lilly - Investing.com Nigeria
Ventyx Biosciences (VTYX) investors approve Eli Lilly merger and executive pay - Stock Titan
Insider Sell: Is Skyward Specialty Insurance Group Inc attractive at current valuationWeekly Trend Recap & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
VTYX Should I Buy - Intellectia AI
Ventyx Biosciences Inc. (VTYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Pharmaceutical Stocks To Follow NowFebruary 27th - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
GLAZER CAPITAL, LLC Acquires Significant Stake in Ventyx Bioscie - GuruFocus
Ventyx Faces Eli Lilly Acquisition, Delisting and Litigation - TipRanks
Ventyx Biosciences agrees to $14.00 cash per share merger with Eli Lilly; HSR waiting period cleared - TradingView
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):